Sangamo Therapeutics (NASDAQ: SGMO)
Sangamo Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Sangamo Therapeutics Company Info
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.
News & Analysis
CRISPR 101: What Investors Need to Know
Here's an overview of the opportunities in gene editing and CRISPR technology.
3 Top Biotech Stocks to Watch in July
These three stocks are positioned for growth -- but investors must tread carefully in the short term.
Pfizer and Sangamo's Gene Therapy Continues to Help Patients with Hemophilia in Clinical Trial
While the data looks good so far, the duo's treatment is behind a similar BioMarin therapy in the testing and approval process.
Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics
Each company aims to use its genome editing platform to treat disease, but which has an edge?
Better Buy: Cara Therapeutics vs. Sangamo Therapeutics
Which stock wins in a battle between these two clinical-stage biotechs?
Better Buy: Editas Medicine vs Sangamo Therapeutics
Which of these two gene-editing companies is the better investment?
3 Top Stocks You've Probably Never Heard Of
With the coronavirus pandemic on everyone's mind, these three stocks have stayed under the radar.
Better Buy: CRISPR Therapeutics vs. Sangamo Biosciences
With valuations cut in half, investors should consider these promising gene-editing companies.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.